Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Luc_Dochez
|
| gptkbp:developedBy |
antisense oligonucleotide therapies
|
| gptkbp:focusesOn |
rare neurological disorders
RNA modulation therapies |
| gptkbp:foundedYear |
2019
|
| gptkbp:fundedBy |
gptkb:BioGeneration_Ventures
gptkb:EQT_Life_Sciences gptkb:Kurma_Partners gptkb:Forbion |
| gptkbp:headquartersLocation |
gptkb:Leiden,_Netherlands
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vico Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:program |
gptkb:VICO-101
|
| gptkbp:targetsDisease |
gptkb:Huntington’s_disease
gptkb:ALS spinocerebellar ataxia |
| gptkbp:website |
https://vicotx.com/
|
| gptkbp:bfsParent |
gptkb:Luc_Dochez
|
| gptkbp:bfsLayer |
7
|